MedTrace Logo

Platelet Reactivity in PAD Undergoing Percutaneous Angioplasty

NCT04165629 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2020-07-15

No results posted yet for this study

Summary

Dual antiplatelet therapy has a key role in a prevention of thrombosis of treated artery in patients undergoing percutaneous transluminal angioplasty (PTA). Weak therapeutic response and presence of residual platelet activity is related to high risk for stent thrombosis and it is well in known in coronary artery disease (CAD) patients undergoing percutaneous coronary intervention (PCI). However there are few data on the association between a different entity of platelet inhibition on antiplatelet treatment and clinical outcomes in patients with peripheral artery disease (PAD). The aim of this study was to evaluate the degree of on-treatment platelet reactivity, and its association with ischemic and hemorrhagic adverse events at follow up in PAD patients undergoing PTA.

Conditions

Interventions

DRUG

Aspirin 300mg and Clopidogrel 300mg

Aspirin 300mg and Clopidogrel 300mg on the day of the PTA

Sponsors & Collaborators

  • Clinical Centre of Serbia

    lead OTHER

Principal Investigators

  • Petar Zlatanovic, MD · Clinical Center of Serbia

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2022-01-01
Completion
2022-07-01

Countries

  • Serbia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04165629 on ClinicalTrials.gov